ARS Pharmaceuticals, Inc. SPRY Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s cash ratio?
- ARS Pharmaceuticals, Inc. (SPRY) reported cash ratio of 0.5× in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s cash ratio changed year-over-year?
- ARS Pharmaceuticals, Inc.'s cash ratio decreased by 66.0% year-over-year, from 1.4× to 0.5×.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s cash ratio has grown at a -51.7% compound annual growth rate (CAGR), from 40.3× to 1.1×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.